Status:
COMPLETED
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Lead Sponsor:
CHA University
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Advanced Hepatocellular Carcinoma
Eligibility:
All Genders
19+ years
Brief Summary
Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related deaths globally and in Korea. Many patients diagnosed at advanced stage, and systemic therapy is mainstay of treatme...
Detailed Description
In a previous retrospective analysis of pembrolizumab treated patients with advanced melanoma and NSCLC, patients with liver metastases showed poorer PFS compared with those without liver metastases w...
Eligibility Criteria
Inclusion
- Confirmed HCC pathological or non-invasive assessment according to American Association for the Study of Liver Diseases (AASLD) criteria
- ECOG performance status 0 or 1
- Patients who received Atezolizumab and Bevacizumab combination therapy as first-line systemic treatment for unresectable HCC
- Barcelona Clinic Liver Cancer (BCLC) stage B or C
- Child-Pugh class A
- Measurable lesion
- Adequate hematologic and organ function
Exclusion
- History of autoimmune disease
- Concomitant anticoagulation at therapeutic doses. Low dose aspirin for
- cardio protection is permitted.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 9 2023
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT04862949
Start Date
May 1 2021
End Date
March 9 2023
Last Update
December 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cha Medical Center
Seongnam-si, Gyeonggi-do, South Korea, 13496